May 13, 2024 | Diabetes, Kurt Harden, MedBen University, Mounjaro, Ozempic, Wegovy, Weight loss, Zepbound
At recent MedBen University roundtables, MedBen President & CEO Kurt Harden examined how the growing public awareness of two diabetes drugs with a desirable side effect – significant weight loss – means that these $1,000-per-month medications are not always being...
Sep 18, 2023 | Announcements, Diabetes, MedBen Rx, Ozempic, Weight loss
Important information for MedBen Rx clients using the Ventegra formulary: Effective October 1, an appropriate ICD-10 diagnosis code for type 2 diabetes will be required for certain Ozempic prescriptions and all other GLP-1 class medications. Ozempic and other GLP-1...
Mar 21, 2023 | Brand Name Drugs, Diabetes, Generic Drugs, MedBen Rx, MedBen University, Pharmacy Benefits Manager (PBM), Prescription drugs, Rx Costs, Rx prices, Savings
Earlier this month, drug manufacturer Eli Lilly announced that it cutting the cost of two of its prescription brand insulins, Humalog and Humulin, by 70%, and capping out-of-pocket costs for privately insured patients at $35 a month. Competing...
Apr 6, 2021 | Case Study, Comparative Effectiveness, Diabetes, MedBen Rx
MedBen Rx Comparative Effectiveness uses evidence-based research to make sure your members are taking the most effective drugs at the best cost. A MedBen Rx client recently changed their formulary by using Comparative Effectiveness to focus on drugs that would produce...
